Key result
Type 5 phosphodiesterase inhibitors like sildenafil may acutely enhance endothelium-dependent vasodilation in heart failure, though further studies are needed to characterize safety and efficacy.
Why the study?
Is type 5 phosphodiesterase inhibition safe and effective in the treatment of chronic heart failure?
Is type 5 phosphodiesterase inhibition safe and effective in the treatment of chronic heart failure?
Type 5 phosphodiesterase inhibition represents a potential therapeutic target for addressing endothelial dysfunction in heart failure, though further clinical trials are required to establish safety and efficacy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PDE5 inhibition in HF endothelial dysfunction; randomized trials needed before clinical consideration.
Endothelial dysfunction is associated with impairment of aerobic capacity in patients with heart failure and may play a role in the progression of disease. Impaired endothelium-dependent vasodilation in patients with heart failure can be attributed to decreased bioavailability of nitric oxide and attenuated responses to nitric oxide in vascular smooth muscle. Impaired vasodilation in response to nitric oxide derived from vascular endothelium or organic nitrates in vascular smooth muscle may be related in part to increased degradation of the second messenger cyclic guanosine monophosphate by type 5 phosphodiesterase. Sildenafil, a specific type 5 phosphodiesterase inhibitor currently approved for the treatment of erectile dysfunction, has been shown to acutely enhance endothelium-dependent vasodilation in patients with heart failure. Further studies are warranted to characterize the safety and efficacy of type 5 phosphodiesterase inhibition in the treatment of chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Stuart D. Katz (2003) conducted a review in Congestive Heart Failure. Type 5 Phosphodiesterase Inhibition (Sildenafil) was evaluated. Type 5 phosphodiesterase inhibitors like sildenafil may acutely enhance endothelium-dependent vasodilation in heart failure, though further studies are needed to characterize safety and efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: